Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Date:8/5/2011

SAN DIEGO, Aug. 5, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2011.

"Since our last quarterly update, we presented exciting initial results from the ongoing extension portion of our Phase 2b trial of lesinurad demonstrating high rates of sustained uric acid lowering and patient response over week 28 of the study at all doses," commented Barry D. Quart, PharmD, president and chief executive officer. "These results, together with the impressive efficacy and safety profile established in previous studies, position lesinurad very well for our upcoming Phase 3 clinical studies."

Recent Accomplishments and Important Upcoming Events

  • In May 2011, we presented additional positive results from the primary dosing and ongoing extension periods of our Phase 2b study (Study 203) adding lesinurad to allopurinol in patients who did not achieve target serum urate (sUA) levels on allopurinol alone, as well as other preclinical and clinical data from our lesinurad development program, at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR).  Highlights included:
  • Results from the ongoing, blinded extension portion of Study 203 showed that 91 percent of patients receiving lesinurad in combination with allopurinol achieved sUA levels below the clinically important target of 6 mg/dL after 28 weeks of dosing. In addition, continued reductions in sUA were observed beyond the initial 28 days of dosing with the majority of the responding patients remaining on the 200 mg dose of lesinurad thus far in the extension portion. The combination has been generally well toler
    '/>"/>

    • SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Ardea Biosciences to Present at Upcoming Investor Conferences
    2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
    3. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
    4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
    5. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
    6. Ardea Biosciences Prices Public Offering of Common Stock
    7. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    8. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    10. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/20/2013)... Biomarkers and Clinigene International are set to unveil their ... 2013 AAPS/ National Biotechnology Conference May 20-22 ... Marina , San Diego, CA. ... company representatives at their collaborative seminar, "Biosimilarity, Immunogenicity and ... 1-2 p.m. in the conference,s Spinnaker Room. ...
    (Date:5/20/2013)... , May 20, 2013 Cempra, Inc. ... developing differentiated antibiotics to meet critical medical needs ... that it presented data at the American Thoracic ... Philadelphia demonstrating the antibacterial and enhanced ... prior Phase 2 clinical trial in outpatients with ...
    (Date:5/20/2013)... 20, 2013 Interventional cardiologist Tony Farah, ... Hospital (AGH) Cardiovascular Institute have helped pioneer many ... disease (CAD) over the past three decades, from ... angioplasty and coronary artery stent implantation. , Today, AGH ... a prominent role in the study of a novel, ...
    (Date:5/20/2013)... France (PRWEB) May 20, 2013 On ... this time – in Paris - the beautiful city ... congress chairperson, "Personalized Medicine is revolutionizing the medical world. ... clinical knowledge is the hallmark of this transformation. Much ... care derived from the epidemiologic studies of large cohorts ...
    Breaking Biology Technology:Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2
    ... leading MISSION(TM) shRNA ... ... ), a,leading life science company and member of The RNAi Consortium ... ( http://sigma-aldrich.com/rpp ). The RNAi Partnership,Program provides new members with access ...
    ... Conference Call to Discuss Results to Be Held at ... ViroPharma Incorporated,s,(Nasdaq: VPHM ) third quarter financial results ... 29, 2008 before the open of the U.S.,financial markets., ... live audio webcast at 9:00,a.m. Eastern Time on the ...
    ... leader will provide commercialization expertise to company, ... Inc., a company,revolutionizing spine care through the development ... William L. Lister as the,newest member of the ... board,s,Compensation Committee and will focus on guiding the ...
    Cached Biology Technology:Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program 2Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program 3ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008 2Axial Biotech Appoints Retired Roche Diagnostics Executive to Board 2
    (Date:5/20/2013)... - A novel vaccine study from South Dakota ... will be unveiled at the American Association of Pharmaceutical ... place Monday, May 20 - Wednesday, May 22 at ... "The main goal of a vaccine is to stimulate ... causes the disease", explained Dr. Hemachand Tummala, assistant professor ...
    (Date:5/20/2013)... USA New Geology articles posted ... 2013 cover a wide swath of geoscience subdisciplines, ... geophysics, and paleobotany. Locations studied include Siberia; the ... Alpi Apuane, Italy; Ukraine; Mars; and the Southeastern ... 1. Rubies, jadeite, and plate tectonics;, 2. The ...
    (Date:5/19/2013)... strain of electricity-producing bacteria that can grow using hydrogen ... as its sole source of carbon. Researchers at ... the 113th General Meeting of the American Society for ... production solely on hydrogen," says Amit Kumar, a researcher ... part of the Lovley Lab Group at the university. ...
    Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11
    ... DURHAM, N.C. Tree growth and fecundity the ... to climate change than previously thought, according to an ... researchers. The study, published April 5 in ... one of several overlooked factors that affect tree reproduction ...
    ... LANSING, Mich. Monitoring oxygen levels in water has ... more and a professor at Michigan State University ... concept of oxygen sensors isn,t new. The challenge, however, ... temperature, salinity, carbon dioxide, phosphates and biological wastes. Ruby ...
    ... from Northwestern University and Argonne National Laboratory have ... and its remarkable ability to remove strontium from ... scientists design methods to remove radioactive strontium from ... waste component, is one of the more dangerous ...
    Cached Biology News:'Epidemiological' tree study shows impacts of climate change on forests 2Oxygen sensor invention could benefit fisheries to breweries 2Addressing the nuclear waste issue 2Addressing the nuclear waste issue 3
    ... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
    Request Info...
    ... DNase I (RNase-free) (E.C. 3.1.21.1) is ... DNA and chromatin. It functions by hydrolyzing ... a 5'-phosphate and a 3'-hydroxyl group. Ambion's ... purity available and is recommended to degrade ...
    Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
    Biology Products: